BioSpace News Archive

Top companies in the market are focusing on R&D activities to expand their product offerings and cater to unmet medical needs of the global population.

Pieris Pharmaceuticals, Inc. today announced the successful completion of the sponsor safety review of part 1a of the multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated PRS-060/AZD1402.

Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:45 a.m. ET.

Phio Pharmaceuticals Corp. today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn, will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is being held on January 10 – 13, 2022.

Intra-Cellular Therapies, Inc. announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 am ET.

Spero Therapeutics, Inc., announced that the U.S. Food and Drug Administration has granted Priority Review designation and confirmed the acceptance for substantive review of the New Drug Application seeking approval for tebipenem HBr oral tablets for treatment in adult patients with complicated urinary tract infections, including acute pyelonephritis, caused by susceptible microorganisms.

InnerScope Hearing Technologies Inc., an emerging and disruptive leader in the Direct-to-Consumer Hearing Technology space, announces that InnerScope CEO Matthew Moore has been invited to present at the Emerging Growth Conference.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced it has received its final preclinical milestone payment from Dr. Falk Pharma GmbH under its collaboration agreement to develop and commercialize Prometheus’ second program, PR600.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma.

Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), today announced that it has made a confidential submission to the United States Securities and Exchange Commission (“SEC”), for receipt by the SEC on December 27, 2021, of a draft registration statement on Form S-4 (the “Registration Statement”) relating to its previously announced proposed business combination with Blade Therapeutics, Inc. (“Blade”).